Experimental study of the mechanical transmission of rabbit hemorrhagic disease virus (RHDV2/b) by Aedes Albopictus (Diptera: Clicidae) and Phlebotomus papatasi (diptera: psychodidae); 34447999

Rabbit hemorrhagic disease (RHD) is caused by a lagovirus mainly affecting European rabbits (Oryctolagus cuniculus), although other European and North American lagomorph species are also susceptible to fatal infection by the new viral variant RHDV2/b. In the present work, direct mechanical transmission of the rabbit hemorrhagic disease virus (RHDV2/b variant) by the hematophagous Diptera Aedes albopictus (Skuse) (Diptera: Culicidae) and the sand fly Phlebotomus papatasi (Scopoli) (Diptera: Psychodidae) was tested. For each species, six and three laboratory rabbits were exposed to bites of dipterous females partially fed on RHDV2/b viral suspension 2 h and 24 h prior to exposure, respectively. The rabbits were then monitored for clinical changes and mortality for 35 d, and seroconversion was assessed by indirect ELISA. No rabbit died or showed clinical signs of disease, and seroconversion was recorded in two rabbits challenged with P. papatasi females fed the viral suspension 2 h prior to exposure. The number of RHDV2/b RNA copies/female was higher in Ae. albopictus than in P. papatasi but the decrease over time of RNA load in Ae. albopictus was greater than that in P. papatasi. The results of this study suggest the inability of Ae. albopictus to serve as a direct mechanical vector of RHDV2/b, but sand flies could play a role in the local transmission of RHD. © The Author(s) 2021. Published by Oxford University Press on behalf of Entomological Society of America

Servicio de sistemas personalizados de dosificación: coste del servicio frente al margen de los medicamentos

Introducción: La preparación de sistemas personalizados de dosificación (SPD) dentro del servicio de seguimiento farmacoterapéutico (SFT) ha demostrado ser un instrumento que mejora la adherencia terapéutica del paciente. Para la valoración de su remuneración se analiza el coste de este servicio y si el margen de los medicamentos dispensados e incluidos en el SPD cubre su prestación. Objetivos: Establecer un análisis de costes del servicio; averiguar si, en pacientes polimedicados tipo, el margen de los medicamentos incluidos en el SPD cubre los costes, y conocer el número de medicamentos que deberían incluirse cuyo margen cubra la prestación del servicio. Material y métodos: Para el análisis del coste del servicio, se ha considerado el coste de la preparación del SPD y de la intervención farmacéutica más el coste directo del material utilizado. En el análisis de pacientes reales, se ha calculado el margen de los medicamentos incluidos en el SPD y se ha comparado con el coste calculado de la prestación del servicio. Para el análisis del número de medicamentos, se ha tomado como referencia el precio medio de los medicamentos dispensados al CatSalut y el margen medio actual. Resultados: El coste del servicio por paciente y mes (4 semanas) se ha estimado en 19,85 euros. Se necesitarían un mínimo de 8 medicamentos para cubrir este coste. Conclusiones: A partir de los casos analizados, se concluye que es muy difícil cubrir el coste del servicio con el margen de los medicamentos dispensados e incluidos en el SPD. La remuneración debe considerar otros aspectos tras evaluar la eficiencia del servicio

Servicio de sistemas personalizados de dosificación: coste del servicio frente al margen de los medicamentos

Introducción: La preparación de sistemas personalizados de dosificación (SPD) dentro del servicio de seguimiento farmacoterapéutico (SFT) ha demostrado ser un instrumento que mejora la adherencia terapéutica del paciente. Para la valoración de su remuneración se analiza el coste de este servicio y si el margen de los medicamentos dispensados e incluidos en el SPD cubre su prestación. Objetivos: Establecer un análisis de costes del servicio; averiguar si, en pacientes polimedicados tipo, el margen de los medicamentos incluidos en el SPD cubre los costes, y conocer el número de medicamentos que deberían incluirse cuyo margen cubra la prestación del servicio. Material y métodos: Para el análisis del coste del servicio, se ha considerado el coste de la preparación del SPD y de la intervención farmacéutica más el coste directo del material utilizado. En el análisis de pacientes reales, se ha calculado el margen de los medicamentos incluidos en el SPD y se ha comparado con el coste calculado de la prestación del servicio. Para el análisis del número de medicamentos, se ha tomado como referencia el precio medio de los medicamentos dispensados al CatSalut y el margen medio actual. Resultados: El coste del servicio por paciente y mes (4 semanas) se ha estimado en 19,85 euros. Se necesitarían un mínimo de 8 medicamentos para cubrir este coste. Conclusiones: A partir de los casos analizados, se concluye que es muy difícil cubrir el coste del servicio con el margen de los medicamentos dispensados e incluidos en el SPD. La remuneración debe considerar otros aspectos tras evaluar la eficiencia del servicio

Impact of a training project for primary health-care providers (FOCO project) in the HIV screening and HIV late diagnosis

Poster [P043] OBJECTIVE Reducing HIV late diagnosis remains an epidemiological challenge . The objective of this project was to promote early HIV diagnosis through the training of primary health - care providers (PHCP) . METHODS HIV specialists conducted training sessions in 108 primary care centers (PCC) from six Spanish regions during 2016 and 2017 , and with 1804 PHCP involved . The intervention was evaluated using a pre - experimental design collecting the dependent variables both in the six months before and after the intervention . Number of requests for HIV tests from the PCC trained and clinical data of new HIV diagnosed patients were collected . Parametric and non - parametric tests were used to assess differences between pre and post - intervention data . RESULTS 3. Differences in clinical variables in pre and post intervention period

Correlation between centrality metrics and their application to the opinion model

In recent decades, a number of centrality metrics describing network properties of nodes have been proposed to rank the importance of nodes. In order to understand the correlations between centrality metrics and to approximate a high-complexity centrality metric by a strongly correlated low-complexity metric, we first study the correlation between centrality metrics in terms of their Pearson correlation coefficient and their similarity in ranking of nodes. In addition to considering the widely used centrality metrics, we introduce a new centrality measure, the degree mass. The m order degree mass of a node is the sum of the weighted degree of the node and its neighbors no further than m hops away. We find that the B_{n}, the closeness, and the components of x_{1} are strongly correlated with the degree, the 1st-order degree mass and the 2nd-order degree mass, respectively, in both network models and real-world networks. We then theoretically prove that the Pearson correlation coefficient between x_{1} and the 2nd-order degree mass is larger than that between x_{1} and a lower order degree mass. Finally, we investigate the effect of the inflexible antagonists selected based on different centrality metrics in helping one opinion to compete with another in the inflexible antagonists opinion model. Interestingly, we find that selecting the inflexible antagonists based on the leverage, the B_{n}, or the degree is more effective in opinion-competition than using other centrality metrics in all types of networks. This observation is supported by our previous observations, i.e., that there is a strong linear correlation between the degree and the B_{n}, as well as a high centrality similarity between the leverage and the degree.Comment: 20 page

Efficacy of the Vaccine Candidate Based on the P0 Peptide against Dermacentor nitens and Ixodes ricinus Ticks

(This article belongs to the Collection Advances in Tick Research)The control of ticks through vaccination offers a sustainable alternative to the use of chemicals that cause contamination and the selection of resistant tick strains. However, only a limited number of anti-tick vaccines have reached commercial realization. In this sense, an antigen effective against different tick species is a desirable target for developing such vaccines. A peptide derived from the tick P0 protein (pP0) conjugated to a carrier protein has been demonstrated to be effective against the Rhipicephalus microplus, Rhipicephalus sanguineus, and Amblyomma mixtum tick species. The aim of this work was to assess the efficacy of this peptide when conjugated to the Bm86 protein against Dermacentor nitens and Ixodes ricinus ticks. An RNAi experiment using P0 dsRNA from I. ricinus showed a dramatic reduction in the feeding of injected female ticks on guinea pigs. In the follow-up vaccination experiments, rabbits were immunized with the pP0-Bm86 conjugate and challenged simultaneously with larvae, nymphs, and the adults of I. ricinus ticks. In the same way, horses were immunized with the pP0-Bm86 conjugate and challenged with D. nitens larva. The pP0-Bm86 conjugate showed efficacies of 63% and 55% against I. ricinus and D. nitens ticks, respectively. These results, combined with previous reports of efficacy for this conjugate, show the promising potential for its development as a broad-spectrum anti-tick vaccine.This research was funded by the Center for Genetic Engineering and Biotechnology, Havana, Cuba, the Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Portugal, and the Czech Science Foundation grant no. 20-05736S. Mobility was supported by the CYTED Network INCOGARR 110RT0541.info:eu-repo/semantics/publishedVersio

Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.

Leishmaniasis is a protozoan disease caused by parasites of the genus Leishmania, transmitted to humans by sandflies. The diagnosis of leishmaniasis is often challenging as it mimics many other infectious or malignant diseases. The disease can present in three ways: cutaneous, mucocutaneous, or visceral leishmaniasis, which rarely occur together or consecutively. The patient was a 52 years old immunosuppressed Belgian woman with a long history of severe rheumatoid arthritis. She underwent bone marrow biopsy to explore thrombocytopenia. Diagnosis of visceral leishmaniasis was made by identification of Leishman Donovan (LD) bodies in macrophages. Treatment with liposomal amphotericin B was successful. She later developed cutaneous leishmaniasis treated with amphotericin B lipid complex. She next presented with relapsing cutaneous lesions followed by rapidly progressing lymphadenopathies. Biopsy confirmed the diagnosis of leishmaniasis. Treatments by miltefosine, amphotericin B, N-methyl-glucamine antimoniate were subsequently initiated. She later presented a recurrent bone marrow involvement treated with intramuscular paromomycin and miltefosine. She died two years later from leukemia. At the time of death, she presented with a mucosal destruction of the nose. A Leishmania-specific PCR (Polymerase Chain Reaction) identified L. infantum as etiological agent. Clinicians should be aware of the potential concomitant or sequential involvement of multiple anatomic localizations of Leishmania in immunosuppressed patients

Deep Sea Sedimentation

This article offers an overview of the main sedimentary systems defining the geomorphology of deep sea environments from low to high latitudes. Mass-transport deposits, turbidite systems, contourites, volcaniclastic aprons, glacial trough mouth systems, carbonate mounds and other bathyal systems, such as pelagites, hemipelagites, mid-ocean channels and polymetallic mineral deposits, are presented with special attention to their morphology, sediments, processes and controlling factors. The integration of the main systems on the continental margins and adjacent abyssal plains in the North Atlantic and westernmost Mediterranean allows to characterize different sedimentation models.En prens

Measurement of the p-pbar -> Wgamma + X cross section at sqrt(s) = 1.96 TeV and WWgamma anomalous coupling limits

The WWgamma triple gauge boson coupling parameters are studied using p-pbar -> l nu gamma + X (l = e,mu) events at sqrt(s) = 1.96 TeV. The data were collected with the DO detector from an integrated luminosity of 162 pb^{-1} delivered by the Fermilab Tevatron Collider. The cross section times branching fraction for p-pbar -> W(gamma) + X -> l nu gamma + X with E_T^{gamma} > 8 GeV and Delta R_{l gamma} > 0.7 is 14.8 +/- 1.6 (stat) +/- 1.0 (syst) +/- 1.0 (lum) pb. The one-dimensional 95% confidence level limits on anomalous couplings are -0.88 < Delta kappa_{gamma} < 0.96 and -0.20 < lambda_{gamma} < 0.20.Comment: Submitted to Phys. Rev. D Rapid Communication

Measurement of the ttbar Production Cross Section in ppbar Collisions at sqrt{s} = 1.96 TeV using Kinematic Characteristics of Lepton + Jets Events

We present a measurement of the top quark pair ttbar production cross section in ppbar collisions at a center-of-mass energy of 1.96 TeV using 230 pb**{-1} of data collected by the DO detector at the Fermilab Tevatron Collider. We select events with one charged lepton (electron or muon), large missing transverse energy, and at least four jets, and extract the ttbar content of the sample based on the kinematic characteristics of the events. For a top quark mass of 175 GeV, we measure sigma(ttbar) = 6.7 {+1.4-1.3} (stat) {+1.6- 1.1} (syst) +/-0.4 (lumi) pb, in good agreement with the standard model prediction.Comment: submitted to Phys.Rev.Let